Literature DB >> 12900794

A full-likelihood method for the evaluation of causality of sequence variants from family data.

Deborah Thompson1, Douglas F Easton, David E Goldgar.   

Abstract

In many disease genes, a substantial fraction of all rare variants detected cannot yet be used for genetic counselling because of uncertainty about their association with disease. One approach to the characterization of these unclassified variants is the analysis of patterns of cosegregation with disease in affected carrier families. Petersen et al. previously provided a simplistic Bayesian method for evaluation of causality of such sequence variants. In the present report, we propose a more general method based on the full pedigree likelihood, and we show that the use of this method can provide more accurate and informative assessment of causality than could the previous method. We further show that it is important that the pedigree information be as complete as possible and that the distinction be made between unaffected individuals and those of unknown phenotype.

Mesh:

Year:  2003        PMID: 12900794      PMCID: PMC1180690          DOI: 10.1086/378100

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  7 in total

1.  Missense mutations in disease genes: a Bayesian approach to evaluate causality.

Authors:  G M Petersen; G Parmigiani; D Thomas
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

2.  Programs for Pedigree Analysis: MENDEL, FISHER, and dGENE.

Authors:  K Lange; D Weeks; M Boehnke
Journal:  Genet Epidemiol       Date:  1988       Impact factor: 2.135

3.  Nine novel conserved motifs in BRCA1 identified by the chicken orthologue.

Authors:  B J Orelli; J M Logsdon; D K Bishop
Journal:  Oncogene       Date:  2001-07-19       Impact factor: 9.867

4.  BRCA1 R841W: a strong candidate for a common mutation with moderate phenotype.

Authors:  D F Barker; E R Almeida; G Casey; P R Fain; S Y Liao; I Masunaka; B Noble; T Kurosaki; H Anton-Culver
Journal:  Genet Epidemiol       Date:  1996       Impact factor: 2.135

5.  Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.

Authors:  Thomas S Frank; Amie M Deffenbaugh; Julia E Reid; Mark Hulick; Brian E Ward; Beth Lingenfelter; Kathi L Gumpper; Thomas Scholl; Sean V Tavtigian; Dmitry R Pruss; Gregory C Critchfield
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

6.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.

Authors:  D F Easton; D T Bishop; D Ford; G P Crockford
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

7.  Strategies for multilocus linkage analysis in humans.

Authors:  G M Lathrop; J M Lalouel; C Julier; J Ott
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

  7 in total
  53 in total

1.  Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2.

Authors:  David E Goldgar; Douglas F Easton; Amie M Deffenbaugh; Alvaro N A Monteiro; Sean V Tavtigian; Fergus J Couch
Journal:  Am J Hum Genet       Date:  2004-08-02       Impact factor: 11.025

Review 2.  Functional analysis of human BRCA2 variants using a mouse embryonic stem cell-based assay.

Authors:  Sergey G Kuznetsov; Suhwan Chang; Shyam K Sharan
Journal:  Methods Mol Biol       Date:  2010

3.  Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.

Authors:  Marcelo A Carvalho; Sylvia M Marsillac; Rachel Karchin; Siranoush Manoukian; Scott Grist; Ramona F Swaby; Turan P Urmenyi; Edson Rondinelli; Rosane Silva; Luis Gayol; Lisa Baumbach; Rebecca Sutphen; Jennifer L Pickard-Brzosowicz; Katherine L Nathanson; Andrej Sali; David Goldgar; Fergus J Couch; Paolo Radice; Alvaro N A Monteiro
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

4.  Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.

Authors:  Marc Tischkowitz; Nancy Hamel; Marcelo A Carvalho; Gabriel Birrane; Aditi Soni; Erik H van Beers; Simon A Joosse; Nora Wong; David Novak; Louise A Quenneville; Scott A Grist; Petra M Nederlof; David E Goldgar; Sean V Tavtigian; Alvaro N Monteiro; John A A Ladias; William D Foulkes
Journal:  Eur J Hum Genet       Date:  2008-02-20       Impact factor: 4.246

5.  Functional assays for classification of BRCA2 variants of uncertain significance.

Authors:  Daniel J Farrugia; Mukesh K Agarwal; Vernon S Pankratz; Amie M Deffenbaugh; Dmitry Pruss; Cynthia Frye; Linda Wadum; Kiley Johnson; Jennifer Mentlick; Sean V Tavtigian; David E Goldgar; Fergus J Couch
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

6.  How genetic variant libraries effectively extend gene testing patents: implications for intellectual property and good clinical care.

Authors:  Sean McElligott; Robert I Field; Mirar Bristol-Demeter; Susan M Domchek; David A Asch
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

7.  BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management.

Authors:  Noralane M Lindor; David E Goldgar; Sean V Tavtigian; Sharon E Plon; Fergus J Couch
Journal:  Oncologist       Date:  2013-04-24

8.  Genetic evidence and integration of various data sources for classifying uncertain variants into a single model.

Authors:  David E Goldgar; Douglas F Easton; Graham B Byrnes; Amanda B Spurdle; Edwin S Iversen; Marc S Greenblatt
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

9.  Missense mutations in cancer predisposing genes: can we make sense of them?

Authors:  Rodney J Scott; Cliff J Meldrum
Journal:  Hered Cancer Clin Pract       Date:  2005-08-15       Impact factor: 2.857

10.  A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example.

Authors:  Leila Mohammadi; Maaike P Vreeswijk; Rogier Oldenburg; Ans van den Ouweland; Jan C Oosterwijk; Annemarie H van der Hout; Nicoline Hoogerbrugge; Marjolijn Ligtenberg; Margreet G Ausems; Rob B van der Luijt; Charlotte J Dommering; Johan J Gille; Senno Verhoef; Frans B Hogervorst; Theo A van Os; Encarna Gómez García; Marinus J Blok; Juul T Wijnen; Quinta Helmer; Peter Devilee; Christi J van Asperen; Hans C van Houwelingen
Journal:  BMC Cancer       Date:  2009-06-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.